LX-APR-009
Summary This protocol describes a 3D endothelial tube formation assay using HUVECs co-cultured with pericytes or mesenchymal stromal cells in LunaX ECM. The model supports mechanistic angiogenesis research, preclinical screening…
LX-APR-008
Summary This protocol adapts standard tissue histology methods for paraffin embedding and sectioning of LunaX hydrogel constructs. It covers fixation, graded dehydration, clearing, paraffin infiltration, embedding and microtome sectioning for…
LX-APR-007
Summary This protocol covers OCT embedding, cryosectioning, staining and imaging of fixed LunaX hydrogel constructs. It supports histology, histochemistry, immunohistochemistry and immunofluorescence for high-resolution analysis of cellular structures, proteins and…
LX-APR-006
Summary This protocol describes whole-mount immunofluorescence staining of intact 3D cultures encapsulated in LunaX hydrogels. It supports visualisation of nuclear, cytoskeletal, cell-surface and intracellular targets without sectioning, using widefield or…
LX-APR-005
Summary This protocol provides starting conditions for differentiating C2C12 myoblasts into contractile myotubes within LunaX ECM. The tuneable 3D matrix supports skeletal muscle modelling across physiologically relevant stiffness conditions while…
LX-APR-004
Summary This protocol measures invasive outgrowth from preformed cancer spheroids embedded within LunaX ECM. The 96-well model surrounds each spheroid with a tuneable 3D matrix for studying stiffness-dependent invasion, treatment…
LX-APR-003
Summary This protocol quantifies invasive outgrowth from preformed cancer spheroids seeded onto LunaX ECM hydrogels. The 96-well assay supports comparisons of matrix stiffness, treatment effects and intrinsic invasive potential using…
LX-APR-002
Summary This protocol describes the encapsulation of primary tumour-derived cells in LunaX CoreMatrix Low Stiffness ECM to establish patient-derived organoids. It provides starting conditions for reproducible 30 µL dome cultures…
LX-APR-001
Summary This protocol describes how to isolate viable primary tumour cells from fresh biopsies or resected cancer tissue and expand them to approximately 80% confluence. The resulting cultures provide a…
